Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma . (2024). Medical Forum Monthly, 35(6). https://medicalforummonthly.com/index.php/mfm/article/view/4698